Financials
AFSA was semi-dormant for a few years, but in 2023 we decided to kick the organization into high gear. While the number of medical journal reports on fibromyalgia continues to grow, most of the focus is headed in the wrong direction. Patients don’t need more hyped-up studies about the marvels of exercise and behavioral therapies, they need (and deserve) more investigations that will significantly impact their care.
Fibromyalgia research must be redirected toward patient needs, such as improved treatments, objective biomarkers, and a better understanding of what causes this disease. AFSA’s small research grants program is essential for steering studies in the direction of patient-relevant projects. Although the National Institutes of Health funds research, learn why you can’t count on it for improving your care.
In November of 2023, AFSA announced its request for applications (RFA) to over 50 investigative teams whose areas of study are aligned with our research-funding mission. We awarded two grants in June and a third grant was awarded in July. See our Projects Funded section for details. And for those interested, we posted a new RFA to continue our research-funding mission (see Grant Guidelines).
While the 2023 RFA trims our cash reserves by 20 percent ($215,138), we plan to engage in active fundraising so that we can continue to award multiple grants each year. In the meantime, we are happy to share with you graphs of our asset balances and financial summaries for the past three years. Our fiscal year is from July 1st through June 30th, so the data for 2023 includes the funding of two of the three grant awards.
If you would like to download our IRS Form 990 for our last three fiscal years, they are available below as PDFs. In addition, our Articles of Incorporation, Bylaws, IRS Determination Letters (initial and 5-year approval), Conflict of Interest Policy, and other governing policies are available.
